Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
React to this article
Latest news
Date Title
01:51p GUNPOINT EXPLORATION : Closes Option Agreement to Sell 100% Interest in Talapoosa Project
01:50p KONICA MINOLTA : "Image Processing Device, Image Processing Method, Image Processing System, and Computer-Readable Non-Transitory Recording Medium" in Patent...
01:50p STRYKER : Spine to Launch New Anterior Cervical Plating System at the American Academy of Orthopaedic Surgeons
01:50p An Application for the Trademark "EVERFLAT" Has Been Filed by Xerox
01:50p BUSINESS MACHINES : Patent Issued for Exposed-Pipeline Processing Element with Rollback
01:50p CGSC Launches New and Responsive MGA Offering for the Miscellaneous Professional Liability Insurance Market
01:50p C&A Marketing Adds SkyMall to Growing Portfolio of Iconic Brands
01:49p CAVIUM : Patent Issued for High Speed Variable Bandwidth Ring-Based System
01:49p ATCO : Gas Wins National Public Safety Award
01:49p HONDA MOTOR : Patent Issued for Vehicle Surroundings Monitoring Device
Latest news
Advertisement
Hot News 
CEB RESOURCES : Sale of Interest in Balamara Resources Limited
FINANCIER CROI INV : Dissertation research ; Letters
EveryWare Global, Inc. Reaches Restructuring Agreement to Create Strengthened Balance Sheet and Sustainable Capital Structure
HYDRODEC : To Acquire Eco-Oil International For GBP2.4 Million
EVOCUTIS : First Half Loss Narrows, Seeking Further Investments
Most Read News
03/31 Wall St. drops but S&P, Nasdaq register quarterly gains
03/31 DEUTSCHE LUFTHANSA : Nick Clegg: don’t let Andreas Lubitz distort views about mental illness
03/31 FOREMOST INCOME FUND : Reports 2014 Results
03/31 SHANTA GOLD : New Loan Facilities
03/31 NEW FLYER : Winnipeg Bargaining Unit Collective Bargaining Agreement Extension
Most recommended articles
01:49p Italy sees extra leeway for growth measures in 2015 budget - sources
01:46pDJNorth Carolina Religious Freedom-Bill on Hold
01:46pDJKBR Charged With Violating Whistleblower Protection Rule
01:44pDJCompagnie de Saint-Gobain Acquisition
01:40pDJArkansas Governor Calls for Changes to Religious-Freedom Bill--3rd Update
Dynamic quotes  
ON
| OFF